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Evidence suggests that research protocols often lack important information on study design, which hinders external
review. The study protocol should provide an adequate explanation for why the proposed study methodology is
appropriate for the question posed, why the study design is likely to answer the research question, and why it is
the best approach. It is especially important that researchers explain why the treatment difference sought is
worthwhile to patients, and they should reference consultations with the public and patient groups and existing
literature. Moreover, the study design should be underpinned by a systematic review of the existing evidence,
which should be included in the research protocol. The Health Research Authority in collaboration with partners
has published guidance entitled ‘Specific questions that need answering when considering the design of clinical trials’.
The guidance will help those designing research and those reviewing it to address key issues.
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Safe advances in health care require that we are able to
appraise critically both the proposed design and the
subsequent results of clinical studies. Proper design is
crucial to a study’s success and ethical acceptability,
and sample size is a major component of design [1].
Our recent review of sample size determinations in
research protocols for randomised clinical trials submitted
to United Kingdom research ethics committees (RECs)
found that most did not contain sufficient information to
allow the sample size to be reproduced, or the plausibility
of the assumed treatment effect or variability used in the
calculation to be assessed [2,3]. Overall, only 55 out of 446
(12%) protocols reported both the data on which the treat-
ment effect sought was based and its clinical importance;
135 (30%) protocols reported the data only and 256 (57%)
reported neither. Limited information on the nature of the
data underpinning the treatment effect was usually given,
and just 13 (3%) protocols gave a reasoned explanation
why the value chosen was plausible for the planned study.
Our research raised the question of whether rando-
mised controlled trials are appropriately designed to* Correspondence: hughdavies@nhs.net
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greater transparency in the reporting of the determin-
ation of the sample size and more focus on study design
during the ethical review process were needed to allow
deficiencies to be resolved early, before the trial begins.
The Health Research Authority (HRA) in collaboration
with the University of Munich and other partners has
now developed necessary guidance entitled ‘Specific
questions that need answering when considering the
design of clinical trials’. This guidance, which lays out
questions that researchers, sponsors, peer reviewers
and ethics committees should ask when planning or
reviewing clinical studies, has been published on the
HRA website [4]. The complete guidance is provided
in Additional file 1.
Main text
The HRA Guidance
This HRA guidance poses five questions [4]:
1) Is there a clear research question?
2) Will the proposed study design answer the
research question?
3) Are the assumptions used in the sample size
calculation appropriate?d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the trial?
5) How will the trial be registered and subsequently
published?
Document structure
The HRA guidance is separated into four layers, providing
increasing detail, as required. Layer I sets out in tabular
form the questions and considerations that researchers,
sponsors, peer reviewers and RECs should ask. By clicking
over a question or specific words or phrases in the table in
Layer I the reader can navigate to a more detailed dis-
cussion of the topic in Layer II. From Layer II the reader
can navigate to more comprehensive explanations of indi-
vidual components of the sample size in Layer III. Finally,
Layer IV provides explanatory notes on some underlying
statistical principles.
The five questions
The HRA guidance is built on the following core con-
cepts: that sound planning is critical to the outcome of
an interventional clinical trial and its ethical acceptability
(bad science is bad ethics); all trials must be registered;
and the results should be published [5,6]. A researcher
should identify the primary research question to be
answered; explain why it is important to patients and
health-care practitioners; show that the study design
is appropriate to answer the question posed, in particular
that the sample size is likely to be adequate to meet the
pre-specified aims of the study; and describe the plan to
disseminate the results of the study.
Is there a clear research question?
The definition of the research question is key to research
design. All research must have a primary question, clearly
stated in advance, and founded on a systematic review of
what is already known [5,7-9]. Researchers who plan stud-
ies without reviewing what has been done, risk performing
research for which the answer is already known or ex-
posing participants to ineffective or an inferior treat-
ment [8-10].
The planning of a clinical trial depends on the primary
question, and researchers should clearly and simply
explain in the study protocol what the trial is aiming to
show, why it is worth asking and, through consultation
with public and patient groups, why this is worthwhile
to patients. The primary question should be consistently
stated throughout the study protocol. Population, inter-
vention, comparator and outcome (PICO) is one useful
way of formulating a research question [11].
Will the proposed design answer the research question?
The research protocol should explain how the proposed
study methodology is appropriate for the question posed,demonstrate that the design is likely to answer the
research question, and why it is the best approach. The
design should be underpinned by a systematic review of
the existing evidence, which should be reported in the
protocol [8,9]. Absence of a systematic review raises the
question: what is the design based on?
Unfortunately, our and other research has found that
study protocols often lack important information on
study design, which hinders external review [2,3,7,12].
The HRA guidance therefore encourages researchers to
explain:
 how the proposed research method is appropriate
for the question posed
 the reasoning behind the choice of any treatment
difference sought, as well as the other parameters
used in the determination of the sample size
 how the relevant successes and failures of previous
studies have been taken into account in the design
of the planned trial
 the reason for the choice of comparators
 the randomisation and blinding methods
 the suitability of the statistical tests
 how the sample to be studied is representative and
thus, generalisable to the wider group of patients
Are the assumptions used in the sample size calculation
appropriate?
Researchers should provide all the information needed
to allow an independent reviewer to both reproduce the
target sample size and understand the rationale for the
assumptions used in the calculation. The HRA guidance
provides a checklist of the information that should be re-
ported in the study protocol for the sample size determin-
ation. Each item is linked to more detailed explanations.
Specific guidance is given on reporting sample sizes based
on confidence intervals, group sequential, factorial, cluster
and time-to-event studies.
The sample size determination checklist requests that
researchers:
 Explain what the study is aiming to show
 Describe the design of the study
 State clearly the primary outcome measure
 State the test procedure on which the sample
size is based
 State the allocation ratio
 State and justify the difference sought, if the
study is aiming to show superiority
 State and justify the acceptance margin,
if the study is aiming to demonstrate
non-inferiority or equivalence
 Report all parameters used in the sample size
calculation
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 Describe any procedures to re-estimate the sample
size during the study
 Report the Type I error
 Report the Type II error
 Describe any adjustments for multiple testing
(multiplicity), if the study has multiple endpoints,
interim analyses, or multiple arms
 State the number of patients or events required for
the analysis
 Explain the allowance (if any) for dropouts
 State the total number of patients to be enrolled
Particular emphasis is placed on the need to provide a
reasoned explanation of why the treatment difference and
other design assumptions are plausible for the planned
study, taking into account all existing data. The import-
ance of the difference sought, i.e. why it is worthwhile to
patients, should also be explained. The justification could
include reference to consultations with the public and
patient groups, existing literature or published studies in
which the minimum clinically important difference has
been empirically determined.
Researchers should be rigorous in the determination
of design assumptions [1-3]. Sample size re-estimation
should be considered if there is a high degree of uncer-
tainty [13]. Manipulating the sample size calculation,
sometimes called the sample size ‘game’ or ‘samba’, to pro-
duce the desired statistical power by inappropriately over-
estimating the treatment effect (known as ‘optimism
bias’ – the unwarranted belief in the efficacy of new
therapies) or underestimating the variability leads to
‘underbuilt’ studies with insufficient power and inconclu-
sive results [14,15]. Such studies are not ethical and waste
valuable resources [16-18].
Sample size determinations must be realistic [19]. If the
sample size required to detect the treatment difference of
interest is unfeasible, then this should be explained in the
research protocol. A well-designed and implemented trial,
even one with lower power (and precision), will still yield
unbiased results, which can be combined with similar
unbiased trials in a meta-analysis [14].
How will safety and efficacy be monitored during the trial?
All studies should be monitored for protocol compliance,
adverse effects, patient recruitment, etc. If treatment is of
long duration then accumulating efficacy data should be
monitored for overwhelming evidence of efficacy or harm.
No study should continue to recruit patients once the
main comparisons have revealed clear-cut differences [5].
The repeated significance testing of accumulating data
does have statistical implications [5]. Thus, the research
protocol should describe how multiple testing has beenaccounted for in the sample size determination [2,3,7]. If
there is a great deal of uncertainty surrounding the
design assumptions then researchers are asked to con-
sider re-estimating the sample size during the course of
the study.
How will the trial be registered and subsequently
published?
For clinical trials, HRA has now established that a
favourable REC opinion is contingent upon trial registra-
tion in publicly accessible databases, unless acceptable
reasons are provided for not doing so. The REC also
needs to be assured that results will be placed in the
public domain. Researchers are expected to:
 publish their results in full and in a reasonable
timescale, even when they do not match
expectations
 follow reporting guidelines for clinical trials (e.g.,
CONSORT [20])
 discuss their findings in the context of an updated
systematic review of relevant research
 provide their results to others doing systematic
reviews of similar topics
Conclusion
It is axiomatic that bad science is bad ethics. Poor re-
search design puts us all at risk. Participants may be ex-
posed to an inferior treatment, or enrolled in trials that
provide no useful information on which to build health
care. Present and future patients may receive ineffective
treatment. Our collaboration provided evidence that we
need to address the design of clinical trials; our guidance
will help those designing such research and those
reviewing it to address key issues, facilitating ethical re-
search that will underpin and improve health care, a key
role for HRA.
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